Nanotechnology Drug Delivery Market (Technology: Nanocrystals, Nanoparticles, Liposomes, Micelles, Nanotubes, and Others; and Application: Neurology, Oncology, Cardiovascular/Physiology, Anti-inflammatory/Immunology, Anti-infective, and Others)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The global nanotechnology drug delivery market size was exhibited at USD 89.37 billion in 2022 and is projected to hit around USD 177.62 billion by 2032, growing at a CAGR of 7.11% during the forecast period 2023 to 2032.

Nanotechnology Drug Delivery Market: Overview

• The role of technology in the delivery of medicine assures revolutionary advances in measuring the size of the particles in nanometer ranges
• One important and active application area of nanotechnology drug delivery systems (DDS) is to transport drugs to the final location of therapeutic intervention within the body. Various organic and inorganic nanomaterials have been utilized for DDS applications.
• The term nano pharmaceuticals (nano drugs) cover different nano-based DDS that can be used to encapsulate drugs for better targeting than with conventional drugs
• The most common nanomaterials utilized for DDS include nanocrystals, liposome, protein-conjugate, dendrimers, and nanoparticles

Nanotechnology Drug Delivery Market Report Scope

Developing Potential of Existing Pharmaceutical Drugs: Key Driver

• The global pharmaceutical industry has been developing compounds for over a century. However, several of these never got to the market. Acceptance of new drug formulations is expensive and slow, taking up to 15 years to obtain accreditation of new drug formulas with no guarantee of success.
• Antineoplastic agents are highly effective in cancer treatment; however, it leads to chronic side effects due to cytotoxic properties and lack of target specificity. Hence, pharmaceutical companies are developing innovative drug delivery systems to increase target specificity for the cytotoxic drugs that are already present in the market.
• New drug delivery compounds are likely to extend the product and patent lifecycles of drugs, enabling the creation of new chemical entities (NCEs) via reformulation of existing and/or orphaned compounds, and subsequent creation of value for shareholders and consumers
• Therefore, renewing the product lifecycle of existing drugs is expected to boost market growth during the forecast period

Clinical Advantages of Nanotechnology in Drug Delivery: Major Driver

• Benefits of nanotechnology-based drug delivery systems for both doctors and patients are lower drug toxicity, more specific targeting, and reduced cost of treatment
• Presently, several drug entities fail clinical trials because the compound is incapable to reach the targeted site without exhibiting any side effects. Delivery of a compound to specific target site is one of the most integral parts of any treatment ranging from infections to cancer.
• The overall drug consumption and side effects can be lowered significantly using nanotechnology drug delivery. The highly selective approach reduces the side effects and cost as well.
• These factors are likely to propel the global nanotechnology drug delivery market during the forecast period

Expanding Pharmaceutical Drug Development Companies Globally

There is a flourishing growth of pharmaceutical companies across the globe. Rising investment in R&D activities in drug development and discovery is contributing to expansion of the nanotechnology drug delivery market. The global pharmaceutical industry has been developing compounds for over a century. Many of these never reached the market. The acceptance of new drug formulations is expensive and slow process. It takes so many years to obtain accreditation of new drug formulas with no guarantee of success. Antineoplastic agents are highly effective in cancer treatment. However, it leads to chronic side effects due to cytotoxic properties and lack of target specificity. Hence, pharmaceutical companies are developing innovative drug delivery systems in order to increase target specificity for the cytotoxic drugs that are already present in the market.

Clinical Advantages of Nanotechnology in Drug Delivery

The global nanotechnology drug delivery market has been classified into nanocrystals, liposomes, micelles, nanoparticles, nanotubes, etc. There has been a major role of a technology in the delivery of medicine to measure the size of the particles in nanometer ranges. The rising acceptance of nanotechnology-based drug delivery systems for both doctors and patients is due to lower drug toxicity, more specific targeting, and reduced cost of treatment. Nowadays, several drug entities fail clinical trials, as the compound is incapable to reach the targeted site without exhibiting any side effects. The delivery of a compound to specific target site is the most important part of any treatment ranging from infections to cancer. The overall drug consumption and side effects can be reduced with the help of the nanotechnology drug delivery system.

The nanotechnology drug delivery system is used in the field of neurology, oncology, cardiovascular/physiology, anti-inflammatory/immunology, anti-infective, and others. Oncology is the largest segment of the global market and expected to witness lucrative growth potential in the upcoming years due to rising cancer cases across the globe.

Booming North America Nanotechnology Drug Delivery Market

North America is expected to account for a major market share of the global nanotechnology drug delivery market. Some of the key factors responsible for the market growth are well-established healthcare infrastructure and increase in number of biopharmaceutical companies in the region. The increasing prevalence chronic diseases all over the world demand technologically advanced drug delivery systems. Asia Pacific and Latin America are other attractive markets, which are poised to rise due to the increasing healthcare spending and improving healthcare facilities. This is due to economic growth, rise in spending capacity, surge in prevalence of cancers, and improvement in healthcare infrastructure.

Some of the prominent players in the Nanotechnology Drug Delivery Market include:

• AbbVie Inc. (AbbVie)
• Amgen Inc.
• Aquanova AG
• Bayer AG
• Camarus AB
• Celgene Corporation
• Cytimmune Sciences
• GlaxoSmithKline PLC
• Johnson & Johnson
• Merck & Co., Inc.
• Nanobiotix
• NanoCarrier Co, Ltd
• NanOlogy LLC
• Novartis AG
• Pfizer Inc. (Pfizer)
• Roche Holding AG (Roche)
• Sanofi SA
• Selecta Biosciences Inc.
• Starpharma Holdings Limited
• Taiwan Liposome Co.
• Tarveda Therapeutics

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Nanotechnology Drug Delivery market.

By Technology

• Nanocrystals
• Nanoparticles
  • Dendrimers
  • Gold Nanoparticles
  • Fullerenes
• Liposomes
• Micelles
• Nanotubes
• Others

By Application

• Neurology
• Oncology
• Cardiovascular/Physiology
• Anti-inflammatory/Immunology
• Anti-infective
• Others (Hematology, Ophthalmology, etc.)

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)